RE:RE:RE:Scientists harness light therapy to target and kill cancer cHi Rumpl, just an fyi...The new treatment described in the article is an engineered protein which contains amino acids. Our treatment uses a metal-based compound (TLD-1433), which is not a protein. The above two chemical entities are very different in composition & from an IP standpoint, one does not infringe upon the other. In addition, the two distinct compounds bind to different receptors on a cancer cell....the compound stated in the article binds to EGFR & Rutherrin/TLD 1433 binds to the transferrin receptor for ours. Both of these receptors are overexpressed in cancerous cells, & I believe they are overexpressed to different degrees in GBM, depending on the grade of disease. Perhaps we could adapt our metal-based compound using a particular ligand that could also bind the EGF receptor? Or perhaps both therapies could ultimately be used separately or in combination since each binds to a different receptor. I imagine their precise MoA may also vary?